Evaluation of SARS-CoV-2-Specific T-Cell Activation with a Rapid On-Chip IGRA
Bo Ning, Sutapa Chandra, Juniper Rosen, Evan Multala, Melvin Argrave, Lane M. Pierson, Ivy V. Trinh, Brittany K. Simone, Matthew D. Escarra, Stacy S. Drury, Kevin J. Zwezdaryk, Elizabeth B. Norton, Christopher J. Lyon, Tony Hu
Abstract
Interferon-gamma release assays (IGRAs) that measure pathogen-specific T-cell response rates can provide a more reliable estimate of protection than specific antibody levels but have limited potential for widespread use due to their workflow, personnel, and instrumentation demands. The major vaccines for SARS-CoV-2 have demonstrated substantial efficacy against all of its current variants, but approaches are needed to determine how these vaccines will perform against future variants, as they arise, to inform vaccine and public health policies. Here we describe a rapid, sensitive, nanolayer polylysine-integrated microfluidic chip IGRA read by a fluorescent microscope that has a 5 h sample-to-answer time and uses ∼25 μL of a fingerstick whole blood sample. Results from this assay correlated with those of a comparable clinical IGRA when used to evaluate the T-cell response to SARS-CoV-2 peptides in a population of vaccinated and/or infected individuals. Notably, this streamlined and inexpensive assay is suitable for high-throughput analyses in resource-limited settings for other infectious diseases.